/PRNewswire/ Texas Children s Hospital and Baylor College of Medicine leading COVID-19 subunit vaccine candidate, developed with Biological E. Limited (BE),.
Health experts from the U.S. and France hosted the COVID-19 Disaster Research and Prevention Symposium to share what they have learned during the pandemic.
A team of researchers from universities in California and Texas has found immunization rates for children in Texas for a wide range of diseases, including polio and measles, have dropped steeply during the COVID-19 pandemic.
Biological E to Start Phase III Trial of Covid Vaccine Apr 25, 2021, 15:31 IST
Biological E Limited (BE), a Hyderabad vaccine and pharmaceutical company based, announced that it has completed the Phase I/II clinical trial of its Covid-19 subunit vaccine candidate in India and has obtained approval from the Central Drugs Standard Control Organization (CDSCO) – Subject Expert Committee to begin the phase III clinical trial (SEC).
The phase III clinical trial, which will be conducted at 15 locations across India, will test the immunogenicity and safety of Biological E s SARS-CoV-2 Covid-19 vaccine for protection against Covid-19 disease. The samples will be tested on 1,268 healthy people in the age group, 18 to 80. It ll be part of a broader global phase III research project.
Biological E gets nod to start Phase III clinical trial of Covid vaccine indiatoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatoday.in Daily Mail and Mail on Sunday newspapers.